Zevra Therapeutics, Inc.

ZVRA Healthcare Biotechnology

Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.

9.95 0.32 −3.12%
Market cap
$609.9M
P/E
10.5×
Fwd P/E
10.5×
Dividend yield
—
F-score
6/9
Altman Z
0.63
Beneish M
1.46
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 6 7 6
ROE
28.11% 79.85% 94.80% 34.33%
ROA
12.36% 33.52% 51.85% 20.57%
ROIC
0.00% (153.83%) (65.48%) 0.00%
Return on Tangible Assets
14.30% 42.12% 63.81% 28.27%
Average Days of Receivables
72.84 79.73 65.96 60.33
Free Cash Flow per Share
(0.42) (0.04) 0.21 0.56
Free Cash Flow
(23.71) (1.98) 12.49 33.07
Other line items

Show all line items

Columns are period end dates